These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31713342)

  • 1. Ethical considerations relating to healthcare resource allocation decisions.
    Olver I; Dodds S; Kenner J; Kerridge I; McGovern K; Milligan E; Mortimer R;
    Intern Med J; 2019 Nov; 49(11):1364-1367. PubMed ID: 31713342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing evaluation studies to optimally inform policy: what factors do policy-makers in China consider when making resource allocation decisions on healthcare worker training programmes?
    Wu S; Legido-Quigley H; Spencer J; Coker RJ; Khan MS
    Health Res Policy Syst; 2018 Feb; 16(1):16. PubMed ID: 29471840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining the underpinnings of decisions to allocate public resources to social care: A systematic review.
    Mos P; Reckers-Droog V
    Soc Sci Med; 2024 Aug; 355():117093. PubMed ID: 39067357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Social values and health priority setting in Australia: an analysis applied to the context of health technology assessment.
    Whitty JA; Littlejohns P
    Health Policy; 2015 Feb; 119(2):127-36. PubMed ID: 25267072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Following orders" as a critique on healthcare allocation committees: An anthropological perspective on the role of public memory in bioethical legitimacy.
    Assor Y
    Bioethics; 2021 Jul; 35(6):549-556. PubMed ID: 34318494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical decision making during a healthcare crisis: a resource allocation framework and tool.
    Guidolin K; Catton J; Rubin B; Bell J; Marangos J; Munro-Heesters A; Stuart-McEwan T; Quereshy F
    J Med Ethics; 2022 Aug; 48(8):504-509. PubMed ID: 34021059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing Patient and Societal Interests in Decisions About Potentially Life-Sustaining Treatment : An Australian Policy Analysis.
    Close E; White BP; Willmott L
    J Bioeth Inq; 2020 Sep; 17(3):407-421. PubMed ID: 32964352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors that explain how policy makers distribute resources to mental health services.
    Corrigan PW; Watson AC
    Psychiatr Serv; 2003 Apr; 54(4):501-7. PubMed ID: 12663837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustainability in health care by allocating resources effectively (SHARE) 3: examining how resource allocation decisions are made, implemented and evaluated in a local healthcare setting.
    Harris C; Allen K; Waller C; Brooke V
    BMC Health Serv Res; 2017 May; 17(1):340. PubMed ID: 28486953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tackling wastage and inefficiency in the health sector.
    Parker D; Newbrander W
    World Health Forum; 1994; 15(2):107-13; discussion 114-31. PubMed ID: 8018273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Policy making and roles of health technology assessment.
    Tantivess S
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S88-99. PubMed ID: 19253491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The greatest happiness of the greatest number? Policy actors' perspectives on the limits of economic evaluation as a tool for informing health care coverage decisions in Thailand.
    Teerawattananon Y; Russell S
    BMC Health Serv Res; 2008 Sep; 8():197. PubMed ID: 18817579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Centralized drug review processes: are they fair?
    Mitton CR; McMahon M; Morgan S; Gibson J
    Soc Sci Med; 2006 Jul; 63(1):200-11. PubMed ID: 16427728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical issues in the economics of rationing healthcare.
    Maynard A
    Br J Urol; 1995 Nov; 76 Suppl 2():59-64. PubMed ID: 8535757
    [No Abstract]   [Full Text] [Related]  

  • 15. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada.
    Bentley C; Costa S; Burgess MM; Regier D; McTaggart-Cowan H; Peacock SJ
    BMC Health Serv Res; 2018 May; 18(1):339. PubMed ID: 29739463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy.
    Bentley C; Peacock S; Abelson J; Burgess MM; Demers-Payette O; Longstaff H; Tripp L; Lavis JN; Wilson MG
    Health Res Policy Syst; 2019 Feb; 17(1):17. PubMed ID: 30732616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doctors and allocation decisions: a new role in the new Medicare.
    Cassel CK
    J Health Polit Policy Law; 1985; 10(3):549-64. PubMed ID: 3935718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Representation or reason: consulting the public on the ethics of health policy.
    Mullen C
    Health Care Anal; 2008 Dec; 16(4):397-409. PubMed ID: 17922193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEGITIMACY OF MEDICINES FUNDING IN THE ERA OF ACCELERATED ACCESS.
    Pace J; Pearson SA; Lipworth W
    Int J Technol Assess Health Care; 2017 Jan; 33(6):700-707. PubMed ID: 28893332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.